Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid antibodies differ in aPL cofactor requirement.

L R Sammaritano1, M D Lockshin, A E Gharavi

  • 1Hospital for Special Surgery, Cornell University Medical Center, New York, NY 10021.

Lupus
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome.

Lupus·2018
Same author

Feasibility of Patient-Reported Outcomes Measurement Information System (PROMIS®) computerized adaptive tests in systemic lupus erythematosus outpatients.

Lupus·2018
Same author

Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients.

Arthritis care & research·2016
Same author

Assisted reproductive technology in SLE and APS.

Lupus·2014
Same author

Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome.

Lupus·2014

Autoimmune antiphospholipid antibodies (aPL) binding to phospholipids requires beta 2-glycoprotein I (beta 2GPI) cofactor, but the extent of this requirement varies. The cofactor enhances binding but does not predict clinical complications.

Area of Science:

  • Immunology
  • Biochemistry

Background:

  • Autoimmune antiphospholipid antibodies (aPL) are implicated in thrombosis and pregnancy complications.
  • The role of beta 2-glycoprotein I (beta 2GPI) as a cofactor in aPL binding is not fully understood.
  • It remains unclear if beta 2GPI is essential or merely enhances aPL binding to phospholipids.

Purpose of the Study:

  • To investigate the necessity and extent of beta 2-glycoprotein I (beta 2GPI) cofactor requirement for antiphospholipid antibody (aPL) binding.
  • To determine the binding interaction of aPL with beta 2GPI, phospholipids, or a beta 2GPI-phospholipid complex.
  • To assess the influence of cofactor source (human vs. bovine) and antibody avidity on cofactor dependence.

Main Methods:

  • Purification of beta 2-glycoprotein I (beta 2GPI).

Related Experiment Videos

  • Evaluation of IgG and IgM aPL binding in the presence and absence of beta 2GPI.
  • Comparison of aPL binding to phospholipids with different cofactor conditions and sources.

    • Main Results:

    • Antiphospholipid antibodies (aPL) do not bind beta 2-glycoprotein I (beta 2GPI) without phospholipids.
    • The proportion of aPL binding dependent on beta 2GPI cofactor ranged from 46% to 95%.
    • Human beta 2GPI resulted in enhanced phospholipid binding compared to bovine cofactor, particularly for low-avidity aPL.

    Conclusions:

    • Beta 2-glycoprotein I (beta 2GPI) acts as an enhancing factor, not an absolute requirement, for antiphospholipid antibody (aPL) binding to phospholipids.
    • The degree of cofactor dependence varies among different aPL and does not correlate with clinical manifestations.
    • Understanding cofactor requirements is crucial for accurate aPL diagnostics and understanding their pathogenic mechanisms.